Regeneron Pharmaceuticals (REGN) EBT (2009 - 2026)

Regeneron Pharmaceuticals' EBT history runs 18 years deep, the most recent figure standing at $831.2 million for Q1 2026.

• On a quarterly basis, EBT fell 8.15% year-over-year to $831.2 million in Q1 2026; TTM through Mar 2026 was $5.2 billion, a 3.46% increase from a year earlier, with the FY2025 full-year figure at $5.2 billion, up 9.43% from the prior year.
• EBT fell to $831.2 million in Q1 2026 per REGN's latest filing, from $1.0 billion in the prior quarter.
• Across five years, EBT topped out at $1.8 billion in Q3 2025 and bottomed at $700.7 million in Q1 2024.
• The 5-year median for EBT is $1.1 billion (2023), against an average of $1.2 billion.
• Across the five-year window, EBT slumped 74.33% in 2022 and jumped 50.35% in 2024, its largest moves.
• Year by year, EBT stood at $1.3 billion in 2022, then fell by 13.37% to $1.1 billion in 2023, then fell by 16.51% to $958.1 million in 2024, then gained by 8.93% to $1.0 billion in 2025, then dropped by 20.36% to $831.2 million in 2026.
• Per Business Quant, the three latest REGN EBT figures stand at $831.2 million (Q1 2026), $1.0 billion (Q4 2025), and $1.8 billion (Q3 2025).